NL191789C - Acetylaminoalkaansulfonzuurderivaten met farmacologische eigenschappen. - Google Patents

Acetylaminoalkaansulfonzuurderivaten met farmacologische eigenschappen.

Info

Publication number
NL191789C
NL191789C NL8002997A NL8002997A NL191789C NL 191789 C NL191789 C NL 191789C NL 8002997 A NL8002997 A NL 8002997A NL 8002997 A NL8002997 A NL 8002997A NL 191789 C NL191789 C NL 191789C
Authority
NL
Netherlands
Prior art keywords
acetylaminoalkanesulfonic
acid derivatives
pharmacological properties
pharmacological
properties
Prior art date
Application number
NL8002997A
Other languages
English (en)
Dutch (nl)
Other versions
NL8002997A (nl
NL191789B (nl
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipha filed Critical Lipha
Publication of NL8002997A publication Critical patent/NL8002997A/nl
Publication of NL191789B publication Critical patent/NL191789B/xx
Application granted granted Critical
Publication of NL191789C publication Critical patent/NL191789C/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NL8002997A 1979-05-23 1980-05-23 Acetylaminoalkaansulfonzuurderivaten met farmacologische eigenschappen. NL191789C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7913207 1979-05-23
FR7913207A FR2457281A1 (fr) 1979-05-23 1979-05-23 Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee

Publications (3)

Publication Number Publication Date
NL8002997A NL8002997A (nl) 1980-11-25
NL191789B NL191789B (nl) 1996-04-01
NL191789C true NL191789C (nl) 1996-08-02

Family

ID=9225819

Family Applications (2)

Application Number Title Priority Date Filing Date
NL8002997A NL191789C (nl) 1979-05-23 1980-05-23 Acetylaminoalkaansulfonzuurderivaten met farmacologische eigenschappen.
NL970003C NL970003I2 (nl) 1979-05-23 1997-01-22 Acetylaminoalkaansulfonzuurderivaten met farmacologische eigenschappen.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL970003C NL970003I2 (nl) 1979-05-23 1997-01-22 Acetylaminoalkaansulfonzuurderivaten met farmacologische eigenschappen.

Country Status (18)

Country Link
US (1) US4355043A (no)
JP (2) JPS5625146A (no)
AT (1) AT372371B (no)
AU (1) AU535785B2 (no)
BE (1) BE883468A (no)
CA (1) CA1152100A (no)
CH (1) CH647757A5 (no)
DE (2) DE3019350A1 (no)
ES (1) ES8101042A1 (no)
FR (1) FR2457281A1 (no)
GB (1) GB2051789B (no)
GR (1) GR68547B (no)
IT (1) IT1130455B (no)
MA (1) MA18855A1 (no)
MX (1) MX9203363A (no)
NL (2) NL191789C (no)
OA (1) OA06606A (no)
ZA (1) ZA803051B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU193197B (en) * 1984-02-03 1987-08-28 Egyt Gyogyszervegyeszeti Gyar Preparatives regulating the growth of plants containing as reagent derivatives of n-substituated amin-prophansulphonic acid and process for production of the reagent
JPH0725771B2 (ja) * 1992-06-18 1995-03-22 財団法人生産開発科学研究所 ２−アミノエタンスルホン酸亜鉛錯化合物
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
AU703540B2 (en) * 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) * 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
CN1293573A (zh) * 1998-01-13 2001-05-02 同步神经元有限责任公司 迟发性运动障碍和其它运动疾病的治疗方法
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6265437B1 (en) * 1998-01-27 2001-07-24 Lipha Aminoalkanesulphonic acid derivatives, their preparation and their use as medicaments
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
IL146143A0 (en) * 1999-04-28 2002-07-25 Univ Kingston Compositions and methods for treating amyloidosis
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
MX2007005507A (es) * 2004-11-12 2008-03-13 Neurochem Int Ltd Metodos y composiciones fluoradas para el tratamiento de padecimientos relacionados con amiloides.
AU2005310979A1 (en) * 2004-11-16 2006-06-08 Bellus Health (International) Limited Compounds for the treatment of CNS and amyloid associated diseases
CA2900876A1 (en) 2004-12-22 2006-08-17 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
ATE481094T1 (de) * 2005-12-22 2010-10-15 Kiacta Sarl Behandlung von diabetischer nephropathie
KR101443573B1 (ko) 2006-10-12 2014-11-03 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
AU2007337806A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
KR100877134B1 (ko) * 2007-05-03 2009-01-09 주식회사 엔지켐 아캄프로세이트 칼슘의 제조방법
TW200924747A (en) * 2007-09-07 2009-06-16 Xenoport Inc Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009033079A1 (en) * 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200932734A (en) * 2007-10-15 2009-08-01 Xenoport Inc Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
CN101492400B (zh) * 2008-01-22 2014-03-12 北京华禧联合科技发展有限公司 一种高纯度阿坎酸钙的制备方法
DE102008048791A1 (de) * 2008-09-24 2010-03-25 Merck Patent Gmbh Neue Kristallform von Calcium-3-Acetylaminopropan-1-sulfonat
IT1392327B1 (it) * 2008-09-26 2012-02-28 Laboratorio Chimico Int Spa Nuova forma polimorfa del calcio acamprosato
CN104478766A (zh) * 2014-12-25 2015-04-01 北京华禧联合科技发展有限公司 一种制备高纯度乙酰基高牛磺酸的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3039916A (en) * 1961-03-27 1962-06-19 West Laboratories Inc Anionic iodine complexes
US3544597A (en) * 1969-06-12 1970-12-01 Rohm & Haas Process for manufacturing sulfonated amides
JPS5418714B2 (no) * 1974-10-08 1979-07-10
FR2321285A1 (fr) * 1975-08-18 1977-03-18 Stanley Drug Products Inc Agents antifibrinolytiques
FR2384751A1 (fr) * 1977-03-23 1978-10-20 Francaise Coop Pharma Nouveaux derives de la taurine a activite neuro-musculaire renforcee
US4233229A (en) * 1978-01-03 1980-11-11 Gaf Corporation Preparation of salt-free N-acyl taurines

Also Published As

Publication number Publication date
ZA803051B (en) 1981-06-24
ATA274580A (de) 1983-02-15
BE883468A (fr) 1980-11-24
DE3019350A1 (de) 1980-12-04
MA18855A1 (fr) 1980-12-31
JPH0524135B2 (no) 1993-04-06
GR68547B (no) 1982-01-18
ES491787A0 (es) 1980-12-16
JPH0317825B2 (no) 1991-03-11
FR2457281B1 (no) 1983-10-07
CH647757A5 (fr) 1985-02-15
CA1152100A (en) 1983-08-16
NL8002997A (nl) 1980-11-25
AU535785B2 (en) 1984-04-05
IT1130455B (it) 1986-06-11
FR2457281A1 (fr) 1980-12-19
IT8067807A0 (it) 1980-05-22
NL191789B (nl) 1996-04-01
NL970003I2 (nl) 1997-08-01
MX9203363A (es) 1992-07-01
GB2051789B (en) 1983-04-27
NL970003I1 (nl) 1997-04-01
DE19675017I2 (de) 2001-04-26
ES8101042A1 (es) 1980-12-16
AU5869780A (en) 1980-11-27
AT372371B (de) 1983-09-26
JPS5625146A (en) 1981-03-10
GB2051789A (en) 1981-01-21
US4355043A (en) 1982-10-19
OA06606A (fr) 1981-08-31
JPH03148219A (ja) 1991-06-25
DE3019350C2 (no) 1989-11-30

Similar Documents

Publication Publication Date Title
NL191789C (nl) Acetylaminoalkaansulfonzuurderivaten met farmacologische eigenschappen.
DK343980A (da) 2,4,6-triiod-isophthalsyrederivater
DK343880A (da) 2,4,6-triiod-isophthalsyrederivater
NO791140L (no) Tioetiansyrederivater.
ATE24320T1 (de) Azabicyclo-alkyl-derivate.
NO802946L (no) Imidazo-diazepinderivater
IT8024915A0 (it) Soluzioni.
NO801274L (no) Fjernvarmeroer.
NO163436C (no) Serum-separasjonsroer.
KR840004668A (ko) 5-펜타노익산류
NL7712750A (nl) 1-carba-2-penem-3-carbonzuur en derivaten.
NL7704210A (nl) Fenoxy-fenoxypropionzuurderivaten.
SE7806711L (sv) 7alfa-metoxi-7beta-(1,3-ditietan-2-karboxamido)-cefalosporansyraderivat
NL191740C (nl) Loopplank.
SE8002708L (sv) Penem-3-karboxisyraderivat
NL7704174A (nl) Nieuwe m-fenylfenoxypropionzuurderivaten en de bereidingswijze daarvan.
NO803592L (no) 4,5-umettede prostansyre-derivater.
NL7709788A (nl) 7-acylamino-8-oxo-3-oxa-1-azabicyclo-(4.2.0.)- octaan-2-carbonzuurderivaten.
NL7805747A (nl) Zuur alkalicitraat.
DK501880A (da) Cyclopropancarboxylsyreesterderivater
DK425183D0 (da) 3-hydroxy-24, 24-difluor-25-hydroxycholestand-5,7-dien
NO802888L (no) 2-klor-4,5-disubstituerte-thiazoler
NO802172L (no) Substituerte difenyletere.
NL7705896A (nl) Polyprenylcarbonzuurderivaten.
NL7807871A (nl) Alpha-halogeenmethylaminozuur derivaten.

Legal Events

Date Code Title Description
AC1 Application for a supplementary protection certificate

Free format text: 970003, 970122

KC1 Grant of a supplementary protection certificate

Free format text: 970003, 20000523, EXPIRES: 20050522

SNR Assignments of patents or rights arising from examined patent applications

Owner name: LIPHA

V4 Discontinued because of reaching the maximum lifetime of a patent

Free format text: 20000523